Foundayo reached 7,335 prescriptions in its fourth week on the U.S. market, a number large enough to prove Lilly's oral GLP-1 pill is not dead on arrival and small enough to keep the Wegovy comparison brutal. [1] The drug's week-four print is the first external mark against a launch model that investors had been allowed to imagine rather than measure. The measurement is not flattering. It is useful.

The paper's May 8 standard said Foundayo's week-four IQVIA print would test the 90,000-script bar. The same day's major on Wegovy crossing two million scripts while Foundayo ran into the RBC bar made the broader claim: volume is real, dollars are compressed. Saturday's print makes that split impossible to hide. Lilly has a ramp. Novo has a market.

The Mezha account, drawing on Reuters, reported that Foundayo's 7,335 fourth-week prescriptions indicate moderate demand compared with Novo Nordisk's dominant Wegovy pill. [1] It also reported more than 8,000 prescribers, more than 20,000 patients treated, and analyst expectations that Foundayo would need about 22,000 prescriptions per week to meet expected second-quarter sales of around $160 million. [1] That is the near-term bar. The longer bar is RBC analyst Trung Huynh's estimate that Foundayo must reach more than 90,000 weekly prescriptions by week 12 to stay on track for a $1.4 billion full-year sales model, as carried in prior coverage. [2]

The arithmetic is clinical in its cruelty. Foundayo moved from 5,612 prescriptions in week three to 7,335 in week four, a meaningful rise of roughly 31 percent. [1] But a 31 percent rise off a small base is not the same as escape velocity. To reach 90,000 by week 12, Lilly needs acceleration, not merely growth. It needs prescriber enthusiasm, payer access, pharmacy availability, and patient conversion to compound together. Any one of those can lag. The week-four number says several probably are.

Novo's comparator is not subtle. CNBC reported earlier in the week that Wegovy's pill launch had already forced investors to rethink the oral GLP-1 opportunity, with Foundayo trailing the first mover despite Lilly's broader strength in obesity drugs. [3] Novo's own January launch material put the starter dose of Wegovy pill at $149 per month for self-pay patients, with broad pharmacy and telehealth availability. [4] That price did two things. It opened the door for patients. It squeezed the revenue story.

That is the volume-dollar split. A medicine can touch more households while disappointing the spreadsheet built around richer reimbursement. Wegovy's $149 starter dose creates access, habit, and patient count. It also means prescriptions arrive with less revenue than a benefit-plan model might imply. Novo's first-quarter release, carried through GlobeNewswire, showed adjusted operating profit of DKK 32.858 billion and highlighted the company's GLP-1 growth, but the U.S. pill story beneath the number is a price architecture story as much as a volume story. [5]

For patients, the split is not a problem. It is the promise. Oral GLP-1s have been sold as a way to move obesity treatment from specialist injection culture into ordinary medicine. A cheaper starter dose is how ordinary medicine begins. It lowers the psychological threshold. It creates a pharmacy-counter decision rather than a benefits-department negotiation. It lets a patient try the idea of treatment before accepting the identity of a chronic injectable user.

For companies, the split is a stress test. Novo can accept a cheap starter dose because it owns the first-mover volume and because maintenance-dose conversion can still carry dollars later. Lilly cannot price Foundayo as if Novo's head start does not exist. It must expand access while proving a different molecule can command attention. Dave Ricks told CNBC that more than 20,000 people had started Foundayo in the first few weeks, more than 1,000 people were starting per day, and more than 80 percent were new to GLP-1 drugs. [6] He said the story would play out over quarters, not days. [6] The problem is that markets mark quarters through weekly scripts.

The clinical difference also matters less than launch theorists hoped. Foundayo has convenience arguments. Lilly has brand power through Zepbound and Mounjaro. Yet Wegovy's pill benefits from brand continuity and the fact that many patients already know the name. CNBC noted precisely that contrast: Novo could leverage Wegovy recognition immediately, while Lilly had to introduce an entirely new brand. [3] In medicine, familiarity is a distribution channel.

X reads the 7,335 print as a scoreboard because X likes scoreboards. That instinct is not wrong. A launch that cannot be measured can be narrated forever; a launch with weekly scripts has to answer arithmetic. But the X frame often jumps from lag to failure. That is too fast. Foundayo's prescriber base is wide. Telehealth data may fluctuate. LillyDirect and mail-order channels may be undercounted or delayed in prescription panels. [1] The week-four print is a mark, not a verdict.

Mainstream coverage is more cautious and more corporate. It describes a competitive race between Lilly and Novo, with analyst notes, payer access, and launch timing. [1] [3] That caution is useful but incomplete. The household story is that cheap oral GLP-1s are moving into the daily-life economy. The same drug class that began as a high-priced injection is being normalized through a receipt at the pharmacy counter. That shift can affect weight, blood pressure, fertility, mental health, employer spending, and family budgeting long before it settles which stock deserves the multiple.

The demographic-winter thread sits here because the drugs are not merely treating a condition. They are changing the conditions under which people live. When a million-plus patients start a pill, and a high share are new to GLP-1 treatment, the class becomes a population variable. Novo's public materials describe Wegovy pill as the first and only oral GLP-1 for weight loss in adults, with once-daily use and broad availability. [4] If the access model holds, obesity treatment becomes less like a specialty intervention and more like a monthly household subscription to a different body.

The open question is whether that subscription produces pharma margins or populist medicine. The same $149 starter dose that builds volume also trains patients to expect affordability. The same telehealth distribution that creates access also reduces the old office-visit gate. The same weekly script data that investors use to judge Lilly also lets employers and insurers see demand forming outside them. This is not only a market-share fight. It is a fight over who controls the price of a mass medicine once patients learn it can be cheap enough to try.

Foundayo's week four did not end the race. It ended the fog. Lilly now has a visible curve. Novo has a visible moat. Patients have a visible price. The GLP-1 boom has been sold as a miracle of biology. Saturday's story is the less glamorous miracle of distribution: the pill is moving, but the dollars do not move in the same shape. That is where the next fight begins.

-- NORA WHITFIELD, Chicago